Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Catharina Wenzel"'
Autor:
Rupert, Bartsch, Brigitte, Mlineritsch, Michael, Gnant, Thomas, Niernberger, Ursula, Pluschnig, Richard, Greil, Catharina, Wenzel, Paul, Sevelda, Josef, Thaler, Margaretha, Rudas, Michael, Pober, Christoph C, Zielinski, Guenther G, Steger, K, Wilthoner
Publikováno v:
Breast Cancer Research and Treatment. 115:373-380
Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred
Autor:
Robert M. Mader, Ursula Pluschnig, Guenther G. Steger, Christoph C. Zielinski, Gabriela Altorjai, Catharina Wenzel, Rupert Bartsch, Margaretha Rudas, Michael Gnant
Publikováno v:
Journal of Clinical Oncology. 25:3853-3858
Purpose In human epidermal growth factor 2 (HER-2)–positive advanced breast cancer, taxanes or vinorelbine plus trastuzumab are among the most widely applied options in the first-line setting. We evaluated the efficacy and tolerability of capecitab
Autor:
Ursula Pluschnig, Gabriela Altorjai, Catharina Wenzel, Christoph C. Zielinski, Richard Poetter, Karin Dieckmann, Andrea Rottenfusser, Robert M. Mader, Guenther G. Steger, Rupert Bartsch, Margaretha Rudas
Publikováno v:
Journal of Neuro-Oncology. 85:311-317
Background: Brain metastases are frequently encountered in Her2 positive advanced breast cancer. It is still not clear, if trastuzumab treatment should be continued following their diagnosis. In this analysis we evaluated if trastuzumab was able to i
Publikováno v:
BioDrugs. 21:69-77
Therapeutic antibodies have shown great promise as targeted agents in the treatment of patients with cancer. Trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor-2 (HER-2), is of special importance in breast c
Autor:
Christoph C. Zielinski, Gabriela Altorjai, Guenther G. Steger, Alois Lang, Anton Haid, Catharina Wenzel, Ursula Pluschnig, Dagmar Hussian, Raimund Jakesz, Rupert Bartsch, Michael Gnant
Publikováno v:
Breast Cancer Research and Treatment. 104:109-114
Preoperative chemotherapy in patients with primary breast cancer treated with anthracyclines and taxanes results in high response rates, allowing breast conserving surgery (BCS) in patients primarily not suitable for this procedure. Pathological resp
Autor:
Catharina Wenzel, Guenther G. Steger, Rupert Bartsch, Margaretha Rudas, Gottfried J. Locker, Ursula Pluschnig, Thomas Bachleitner-Hoffmann, Robert M. Mader, Christoph C. Zielinski, Gabriela Altorjai
Publikováno v:
Breast Cancer Research and Treatment. 102:375-381
We evaluated the efficacy and tolerability of oral vinorelbine plus trastuzumab (OV + T) in Her2 positive advanced breast cancer as first line chemotherapy or after progressing on earlier treatment.Thirty consecutive patients (median age: 59 years) w
Autor:
Günther G. Steger, Catharina Wenzel
Publikováno v:
Breast Care. 1:171-175
Adjuvant chemotherapy plays a significant role in improving survival in patients with breast cancer. So far, anthracycline-based combination chemotherapy regimens have demonstrated an advantage over standard cyclophosphamide, methotrexate and 5-fluor
Autor:
Catharina Wenzel, Gottfried J. Locker, Rupert Bartsch, Ursula Pluschnig, Dagmar Hussian, Günther G. Steger, Christoph C. Zielinski, Ursula Sevelda, Michael Gnant, Raimund Jakesz
Publikováno v:
European Journal of Cancer. 41:2655-2661
Fulvestrant (Faslodex) is a new oestrogen receptor (ER) antagonist with no agonist effects. This report describes the experience of a single centre including 126 postmenopausal women with advanced breast cancer (ABC) in a fulvestrant Compassionate Us
Autor:
Guenther G. Steger, Michael Gnant, Rupert Bartsch, Catharina Wenzel, Gottfried J. Locker, Dagmar Hussian, Ursula Pluschnig, Raimund Jakesz, Christoph C. Zielinski, Ursula Sevelda
Publikováno v:
Anti-Cancer Drugs. 16:441-445
The objective of this pilot trial was to evaluate the safety and activity profile of epidoxorubicin, docetaxel and oral capecitabine plus pegfilgrastim (TEX+P) as preoperative first-line treatment for patients with breast cancer. Eleven consecutive p
Autor:
Christoph C. Zielinski, Raimund Jakesz, Margarethe Rudas, Catharina Wenzel, Michael Gnant, Rupert Bartsch, Guenther G. Steger, Dagmar Hussian, Gottfried J. Locker, Ursula Pluschnig
Publikováno v:
Wiener klinische Wochenschrift. 117:48-52
PURPOSE: Preoperative chemotherapy in patients with primary breast cancer results in high response rates, allowing breast-conserving surgery in patients primarily not suitable for this procedure. Tumors of patients with histologically proven breast c